Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 8/20 | 0.38 |
| ▸ | MMP13 | P45452 | 8/20 | 0.38 |
| ▸ | MMP1 | P03956 | 7/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 5/20 | 0.38 |
| ▸ | APP | P05067 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5701916 | 0.85 | CYP2D6 (0.42) | GAACYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL5702210 | 0.85 | CYP2D6 (0.42) | GAACYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL2770703 | 0.79 | CYP3A4 (0.42) | GAAMAPTCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2105715 | 0.71 | APP (0.40) | GAACYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL5701856 | 0.70 | CYP2D6 (0.43) | GAAMAPTCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5702168 | 0.70 | CYP2D6 (0.43) | GAAMAPTCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4004910 | 0.70 | CYP3A4 (0.60) | GAAMAPTCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8502526 | 0.70 | MMP1 (0.46) | MAPTMMP9MMP13MMP1ADAM17 | |
| SCHEMBL28390212 | 0.69 | GAA (0.37) | GAACYP2D6PKMMMP9MMP13 | |
| SCHEMBL8501553 | 0.68 | MMP2 (0.37) | MAPTCYP3A4CYP2C9CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1057894-B1 | Esterase genes and uses of the same | SUMITOMO CHEMICAL CO (JP) | 2010-04-28 | — | — | EP | disclosed |
| EP-1316610-B1 | Preparation comprising an enzyme for asymmetrical hydrolysis of N-substituted C3-C4 cyclic imino-2-carboxylic acid ester and method of using the same | SUMITOMO CHEMICAL CO (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-6936445-B2 | Enzyme preparation and method of using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-08-30 | — | — | US | disclosed |
| US-6828129-B2 | Nucleotide sequences coding polypeptide for use as tool in genetic engineering | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2004-12-07 | — | — | US | disclosed |
| US-6812008-B2 | NUCLEOTIDE SEQUENCES CODING POLYPEPTIDE FOR USE IN THE GENERATION OF S-N-BENZYLAZETIDINE-2-CARBOXYLIC ACID | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20030124683-A1 | Enzyme preparation and method of using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-07-03 | — | — | US | disclosed |
| EP-1316610-A1 | Preparation comprising an enzyme for asymmetrical hydrolysis of N-substituted C3-C4 cyclic imino-2-carboxylic acid ester and method of using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-06-04 | — | — | EP | disclosed |
| US-6537790-B1 | Isolated protein of given sequence which can produce N-substituted cyclic imino acids by hydrolization | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-03-25 | — | — | US | disclosed |
| US-20020173013-A1 | Esterace genes and uses of the same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-11-21 | — | — | US | disclosed |
| US-20020164727-A1 | Nucleotide sequences coding polypeptide for use as tool in genetic engineering | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-11-07 | — | — | US | disclosed |
| EP-1057894-A2 | Esterase genes and uses of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020164727-A1 | Nucleotide sequences coding polypeptide for use as tool in genetic engineering | IMPDH2, INHA, IMPDH1 | GAA 2864/4885MAPT 4852/4885CYP3A4 4456/4885 |
| US-20020173013-A1 | Esterace genes and uses of the same | ACOT7, COASY, IMPA1 | GAA 2267/4885MAPT 4879/4885CYP3A4 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.